updates about the deals, page-25

I thought the second point in the summary of the AGM Presentation is an intetesting one.


• HIV‐1/BIT225• BIT225‐009 Phase 2 trial provides clear clinical evidence that BIT225 is having a unique effect inindividuals infected with HIV‐1

• Engaged with the right potential partners, with the right legal/commercial deal‐making skills in place

• This is not a fast process; but we are focused an achieving a commercial outcome

• Preclinical Programs
• HBV has promise as a preclinical candidate for joint development.

• BIT225 results validate the platform; potential to facilitate funded developments by partners for“other” viral diseases

• Regional Licensing
• HCV in China remains a significant development opportunity – “cost‐conscious” market combinedwith the high rate of co‐infection HCV & HBV requires different approach than used in the USA